Zevra Therapeutics' (NASDAQ:ZVRA) Earnings Aren't As Good As They Appear
Even though Zevra Therapeutics, Inc. ( NASDAQ:ZVRA ) posted strong earnings recently, the stock hasn't reacted in a...
| Ticker |
ZVRA
|
| CIK | 0001434647 |
| SIC | 2834 |
| Sector | Manufacturing |
| Industry Category | Pharmaceutical Products |
| Industry Group | Pharmaceutical Preparations |
| Address | 1180 CELEBRATION BOULEVARD, SUITE 103, CELEBRATION, FL, 34747 |
| Website | kempharm.com |
| Phone | (321) 939-3416 |
| CEO | Travis C. Mickle |
| Employees | 20 |
Our team will help you customize a package that meets the needs of your business.
Request a Consultation|
Standardized FinancialsdocsIntrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals. For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards. Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics: |
|||||||||||||||||||||
|
Income Statement
|
Balance Sheet
|
||||||||||||||||||||
|
Cash Flow Statement
|
Calculations
|
||||||||||||||||||||
|
Latest NewsdocsIntrinio provides up-to-date news articles on every US company from various sources. Here are several examples: |
Zevra Therapeutics' (NASDAQ:ZVRA) Earnings Aren't As Good As They AppearEven though Zevra Therapeutics, Inc. ( NASDAQ:ZVRA ) posted strong earnings recently, the stock hasn't reacted in a... Zevra Therapeutics to Present at the H.C. Wainwright BioConnect Investor ConferenceBOSTON, May 12, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that members of Zevra’s executive leadership team will present at the H.C. Wainwright BioConnect Investor Conference in New York, NY on Tuesday, May 19, 2026, at 9:00 a.m. ET. Additionally, management will be available for one-on-one meetings with registered conference attendees. Zevra Therapeutics, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen NextA week ago, Zevra Therapeutics, Inc. ( NASDAQ:ZVRA ) came out with a strong set of quarterly numbers that could... Is It Too Late To Consider Zevra Therapeutics (ZVRA) After The Recent Share Price Surge?If you are wondering whether Zevra Therapeutics at around US$11.25 is still offering value or if you are late to the story, this article focuses squarely on what the current price might mean for you as an investor. The stock has returned 16.3% over the past week, 15.5% over the past month, 34.9% year to date and 49.8% over the last year, with a very large 3 year return of 157.4% and a 5 year return of 27.7% that many investors are now trying to put into context. Recent attention on Zevra... Zevra Therapeutics Q1 Earnings Call HighlightsZevra Therapeutics (NASDAQ:ZVRA) reported first-quarter 2026 net revenue of $36.2 million, up 78% from the prior-year period, as the company highlighted continued adoption of its Niemann-Pick disease type C (NPC) therapy MIPLYFFA in the U.S., growth in its global expanded access programs, and progre |